WebCLENE NANOMEDICINE™ 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121. CLENE MANUFACTURING CENTER 500 Principio Parkway West Suite 400 North East, Maryland 21901. Contact. 1-801-676-9695 [email protected]. 1-801-676-9695 [email protected] @CleneNano. WebSep 23, 2024 · Clene Nanomedicine: ClinicalTrials.gov Identifier: NCT04098406 Other Study ID Numbers: CNMAu8.205 : First Posted: September 23, 2024 Key Record Dates: Last Update Posted: March 10, 2024 Last Verified: March 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Layout table for additional information ...
Did you know?
WebDec 31, 2024 · Clene expects that its resources as of December 31, 2024, will be sufficient to fund its operations into the third quarter of 2024. Research and development expenses were $31.9 million for the year ended December 31, 2024, compared to $28.4 million for the same period in 2024. WebOur approach implements elemental solutions to discover new therapeutic opportunities and insights into the world’s most challenging diseases. Our singular vision is to transform the treatment of neurodegenerative …
WebClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Thank you for your interest in Clene Nanomedicine! This is an exciting time for us. We have been receiving many requests for more information. We hop … 227 people like this 289 people follow this WebAug 15, 2024 · Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological...
WebMar 18, 2024 · Allison Widlitz has been working as a Vice President, Medical Affairs at Clene Nanomedicine for 2 years. Clene Nanomedicine is part of the Business Services industry, and located in Utah, United States. Clene Nanomedicine. Location. 6550 S Millrock Dr Ste G50, Salt Lake City, Utah, 84121, United States. WebDec 13, 2024 · SALT LAKE CITY, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced a $1 million grant award from …
WebMay 24, 2024 · SALT LAKE CITY, May 24, 2024 -- Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative... April 3, 2024
WebMay 19, 2024 · $3 million 60-month loan to support capital equipment purchases in new 75,000-square-foot facility in Elkton, Maryland, for manufacture of Clene’s lead drug candidate, CNM-Au8®, for treatment of ALS SALT LAKE CITY, May 19, 2024 (GLOBE NEWSWIRE) -- Clene Inc. media expert zwrot onlineWebAug 13, 2024 · 2024-08-13 - By JANE BELLMYER [email protected]. ELKTON — Work has begun on a former W.L. Gore & Associates, Inc. facility in the Chesapeake Corporate Center to transform it into a multi-million dollar production center for Clene Nanomedicine, Inc. “This will be office space, manufacturing and a clean room,” said … pending for long timeWebMar 6, 2024 · SALT LAKE CITY, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.’s January 11, 2024 pending from or withWebClene Nanomedicine, Inc. Expanded/Early Access Policy PURPOSE AND SCOPE Clene is focused on the discovery and development of innovative, life-changing medicines for people with serious and life-threatening diseases. To do this, Clene conducts clinical studies to assess the safety and effectiveness of its investigational medicines. media expert wormsWebMay 24, 2024 · SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today … media expert wolominWebMay 24, 2024 · SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage ... media expert wronkiWeb1 day ago · SALT LAKE CITY, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmace... 3 months ago - GlobeNewsWire Clene Announces Closing of $5 Million Debt Facility from the State of Maryland pending for your reply